Lantern Pharma Announces AI-Powered Module to Advance Antibody-Drug Conjugate (ADC) Development
Lantern Pharma announced advancements in using its RADR® AI platform to accelerate the development of antibody-drug conjugates (ADCs). Lantern Pharma is advancing multiple ADC candidates through preclinical development, including a key collaboration with an initiative at the University of Bielefeld in Germany. In a PLOS ONE peer-reviewed study, Lantern Pharma researchers showcased their AI-driven approach in identifying 82 promising ADC targets and 290 target-indication combinations. Their screening of over 50,000 compounds also validated 729 potential payload molecules. Notably, 22 of these targets have already been confirmed in clinical or preclinical settings, highlighting the platform’s ability to pinpoint clinically relevant targets.
Lantern Pharma Announces AI-Powered Module to Advance Antibody-Drug Conjugate (ADC) Development